Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 936 trials

Stage IV Non-Small Cell Lung Cancer: Immunotherapy and Radiotherapy Study

We are exploring whether combining immunotherapy with extensive radiotherapy is safe and effective for patients with stage IV non-small cell lung cancer. This study will help us understand the treatment's impact on health and quality of life.

Non-small Cell Lung Cancer (Stage IV)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Non-Hodgkin’s Lymphoma: ARV-393 Study

We are evaluating a new treatment called ARV-393 for adults with advanced Non-Hodgkin’s Lymphoma. The goal is to see how well it works and its safety compared to current options.

Advanced Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Oncology

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

Recurrent Glioblastoma1-2 yearsSafety phase (I)No PlaceboStandard MedicinesNeurologyOncology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Sickle Cell Disease: BMS-986470 Study

We are testing a new medication, BMS-986470, to see if it is safe and well-tolerated in healthy volunteers and people with sickle cell disease. The study aims to find the best dose and evaluate its effects on hemoglobin levels.

Sickle Cell DiseaseSafety phase (I)Efficacy phase (II)Investigational MedicinesHematologyInternal Medicine

Acute Myeloid Leukemia: Ziftomenib Combinations

We are investigating the safety and tolerability of Ziftomenib in patients with relapsed or refractory acute myeloid leukemia. This study aims to understand how well this treatment works alongside other therapies.

Relapsed Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Gene Therapy for Central Nervous System Cancer

We are exploring a new gene therapy using stem cells for patients with cancer in the central nervous system. This study aims to see if it can improve treatment outcomes for these patients.

GlioblastomaSafety phase (I)Efficacy phase (II)NeurologyOncology

Acute Myeloid Leukemia: Multi-Peptide Vaccine Study

We are testing a new vaccine to see if it helps AML patients who are in complete remission after their first treatment. The goal is to improve their chances of staying in remission.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Pancreatic, Lung, Breast, and Colorectal Cancers: [177Lu]Lu-NNS309

We are evaluating a new treatment for patients with pancreatic, lung, breast, and colorectal cancers. The study aims to assess its safety and how well it works in these cancer types.

Non-Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)>2 yearsSafety phase (I)Oncology

Type 1 Diabetes: LY3938577 Study

We are assessing a new medication to see how safe it is and how it works in people with type 1 diabetes and healthy participants. This study may help us understand its potential benefits for managing diabetes.

Type 1 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

CRISPR-TIL for Metastatic Melanoma

We are exploring a new treatment using CRISPR to modify immune cells for patients with metastatic melanoma. This study aims to see if it can improve the effectiveness of cancer therapy.

Advanced Melanoma>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Idiopathic Pulmonary Fibrosis: CMR316 Safety Study

We are assessing the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. This study aims to understand how well the treatment is tolerated.

Idiopathic Pulmonary Fibrosis1-2 yearsSafety phase (I)Internal MedicinePulmonology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesOncology

Brain Health: [11C]HSP990 PET Imaging

We are investigating a new imaging agent to measure Hsp90 levels in the brains of healthy individuals and those with neurodegeneration. This study aims to improve our understanding of brain aging and related diseases.

Alzheimer's DiseaseAmyotrophic Lateral SclerosisParkinson's Disease>2 yearsSafety phase (I)NeurologyOtolaryngology

B-cell Malignancies: NX-5948 Treatment Study

We are testing NX-5948 in adults with relapsed or refractory B-cell malignancies. The goal is to see if this new treatment can help those who have not responded to other therapies.

Relapsed/Refractory B-cell Malignancies>2 yearsSafety phase (I)Oncology

Melanoma: Direct Tumor Treatment with Microdosing

We are exploring a new way to deliver treatment directly into tumors for patients with advanced melanoma on anti-PD1 therapy. This pilot study aims to see if this method improves outcomes.

Malignant Melanoma>2 yearsSafety phase (I)DermatologyOncology